ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY

(19)

(11)

EP 1 107 964 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	07.04.2010 Bulletin 2010/14

(45)	Mention of the grant of the patent:
	03.03.2010 Bulletin 2010/09

(21)	Application number: 99942827.9

(22)	Date of filing: 09.08.1999

(51)

International Patent Classification (IPC):

C07D 401/06^(2006.01)
C07D 401/14^(2006.01)
C07D 405/14^(2006.01)

A61K 31/4725^(2006.01)
C07D 401/12^(2006.01)

(86)	International application number:
	PCT/EP1999/005781

(87)	International publication number:
	WO 2000/009495 (24.02.2000 Gazette 2000/08)

(54)	ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY ISOCHINOLINE DERIVATE MIT ANGIOGENESIS-HEMMENDER WIRKUNG DERIVES D'ISOQUINOLINE POSSEDANT UNE ACTIVITE D'INHIBITION DE L'ANGIOGENESE

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
	Designated Extension States:
	RO SI

(30)

Priority:

11.08.1998 CH 165498

(43)	Date of publication of application:
	20.06.2001 Bulletin 2001/25

(73)	Proprietor: Novartis AG
	4056 Basel (CH)

(72)	Inventors:
	ALTMANN, Karl-Heinz CH-4153 Reinach (CH) BOLD, Guido CH-5073 Gipf-Oberfrick (CH) MANLEY, Paul, William CH-4144 Arlesheim (CH)

(74)	Representative: de Weerd, Petrus G.W. et al
	Novartis International AG Corporate Intellectual Property 4002 Basel 4002 Basel (CH)

(56)

References cited: :

WO-A-97/30035
WO-A-98/35958

WO-A-97/34876

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).